Toward enhancement of antibody thermostability and affinity by computational design in the absence of antigen
Open Access
- 20 June 2024
- journal article
- research article
- Published by Taylor & Francis in mAbs
- Vol. 16 (1) , 2362775
Abstract
Over the past two decades, therapeutic antibodies have emerged as a rapidly expanding domain within the field of biologics. In silico tools that can streamline the process of antibody discovery and optimization are critical to support a pipeline that is growing more numerous and complex every year. High-quality structural information remains critical for the antibody optimization process, but antibody-antigen complex structures are often unavailable and in silico antibody docking methods are still unreliable. In this study, DeepAb, a deep learning model for predicting antibody Fv structure directly from sequence, was used in conjunction with single-point experimental deep mutational scanning (DMS) enrichment data to design 200 potentially optimized variants of an anti-hen egg lysozyme (HEL) antibody. We sought to determine whether DeepAb-designed variants containing combinations of beneficial mutations from the DMS exhibit enhanced thermostability and whether this optimization affected their developability profile. The 200 variants were produced through a robust high-throughput method and tested for thermal and colloidal stability (Tonset, Tm, Tagg), affinity (KD) relative to the parental antibody, and for developability parameters (nonspecific binding, aggregation propensity, self-association). Of the designed clones, 91% and 94% exhibited increased thermal and colloidal stability and affinity, respectively. Of these, 10% showed a significantly increased affinity for HEL (5- to 21-fold increase) and thermostability (>2.5C increase in Tm1), with most clones retaining the favorable developability profile of the parental antibody. Additional in silico tests suggest that these methods would enrich for binding affinity even without first collecting experimental DMS measurements. These data open the possibility of in silico antibody optimization without the need to predict the antibody-antigen interface, which is notoriously difficult in the absence of crystal structures.Keywords
All Related Versions
Funding Information
- AstraZeneca (R35-GM141881)
This publication has 37 references indexed in Scilit:
- Engineering the surface properties of a human monoclonal antibody prevents self-association and rapid clearance in vivoScientific Reports, 2016
- Accelerated Formulation Development of Monoclonal Antibodies (mAbs) and mAb-Based Modalities: Review of Methods and ToolsSLAS Discovery, 2015
- High‐throughput cloning and expression library creation for functional proteomicsProteomics, 2013
- Design and Construction of a First-Generation High-Throughput Integrated Robotic Molecular Biology Platform for Bioenergy ApplicationsSLAS Technology, 2011
- Computational design of antibody-affinity improvement beyond in vivo maturationNature Biotechnology, 2007
- Synthetic therapeutic antibodiesNature Chemical Biology, 2006
- Structural mechanism for affinity maturation of an anti-lysozyme antibodyProceedings of the National Academy of Sciences, 2004
- Thermodynamics of antigen-antibody binding using specific anti-lysozyme antibodies.1995
- Three-dimensional structures of the free and the antigen-complexed Fab from monoclonal anti-lysozyme antibody D44.1Journal of Molecular Biology, 1994
- Phage antibodies: filamentous phage displaying antibody variable domainsNature, 1990